Context: The utility of preablation radioiodine scans for the management of differentiated
thyroid cancer remains controversial. Objective: To determine the contribution of preablation …

[en] This study was performed under the auspices of IAEA project (i) to evaluate the efficacy
of low (50 mCi) vs. high (100 mCi) dose I-131 for post operative remnant ablation in …

By far, differentiated thyroid cancer (DTC) is the most common form of thyroid cancer (TC)
accounting for about 90% of all TC in most industrialized countries [1]. Incidence has …

Objective Preablative stimulated thyroglobulin (ps-Tg) is somewhat nonspecific when used
as a predictive marker for distant metastases (DM) from differentiated thyroid carcinoma …

Background: In December 2007, the USFDA approved recombinant human thyroid
stimulating hormone (rhTSH) for radioiodine remnant ablation after total thyroidectomy in …

Results During mean follow-up of 13.7±4.2 years, 20% of patients developed recurrence. At
the end of follow-up, 21% of patients had persistent disease. The clinical and histological …

Objectives To compare the ablation results, therapeutic responses and adverse reactions
between a low dose (1.1 GBq) or high dose (3.7 GBq) of 131 I in low-/intermediate-risk …

Aim: Based on the response criteria of the 2015 American Thyroid Associations guidelines,
our objectives were to determine the response rate when using a low dose of 131-I GBq in …

Radioactive therapy with 131 I (RAI) is commonly used during the management of patients
with differentiated thyroid cancer (DTC). The aim of this study was to determine the clinical …

131 I is given in differentiated thyroid cancer (DTC) without taking into account thyroglobulin
(Tg) levels at the time of ablation, whereas 6–18 months later it is a major criterion for cure …